R5XA Stock Overview A specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. More details
Rewards Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Talphera, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Talphera Historical stock prices Current Share Price US$0.67 52 Week High US$1.33 52 Week Low US$0.46 Beta 0.28 1 Month Change 12.37% 3 Month Change -22.58% 1 Year Change -32.12% 3 Year Change -90.89% 5 Year Change -97.89% Change since IPO -98.92%
Recent News & Updates
Talphera Announces Agreement with the FDA for Prior Approval Supplement Review to Reduce the Number of Patients in the NEPHRO CRRT Study Jan 14
Talphera Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement Dec 12
Talphera Receives a Written Notice from the Listing Qualifications Staff of the Nasdaq Stock Market Nov 30
Third quarter 2024 earnings released: US$0.13 loss per share (vs US$0.085 loss in 3Q 2023) Nov 15
Talphera, Inc. to Report Q3, 2024 Results on Nov 13, 2024 Nov 07
New major risk - Financial position Aug 21 See more updates
Talphera Announces Agreement with the FDA for Prior Approval Supplement Review to Reduce the Number of Patients in the NEPHRO CRRT Study Jan 14
Talphera Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement Dec 12
Talphera Receives a Written Notice from the Listing Qualifications Staff of the Nasdaq Stock Market Nov 30
Third quarter 2024 earnings released: US$0.13 loss per share (vs US$0.085 loss in 3Q 2023) Nov 15
Talphera, Inc. to Report Q3, 2024 Results on Nov 13, 2024 Nov 07
New major risk - Financial position Aug 21
Talphera, Inc. Announces Management Changes Aug 15
Talphera, Inc. to Report Q2, 2024 Results on Aug 14, 2024 Aug 06
Talphera, Inc. Appoints Dr. Shakil Aslam as Chief Development Officer, Effective May 20, 2024 May 16
Talphera, Inc. to Report Q1, 2024 Results on May 14, 2024 May 03
Talphera, Inc., Annual General Meeting, Jun 24, 2024 Apr 21
Talphera, Inc. to Report Q4, 2023 Results on Mar 06, 2024 Feb 27
Talphera, Inc. Appoints Abhinav Jain to Serve as a Class II Director Jan 23
Talphera, Inc.(NasdaqGM:TLPH) dropped from NASDAQ Composite Index Jan 10
Talphera Expects to Initiate the Registrational Study of Niyad Jan 09
New major risk - Financial position Nov 20
AcelRx Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 08, 2023 Oct 27
AcelRx Pharmaceuticals Receives Non-Compliance Notice From Nasdaq Oct 21
AcelRx Pharmaceuticals, Inc. Receives IDE Approval for Niyad and Advances to A Single Registration Study Oct 05
AcelRx Pharmaceuticals, Inc., Annual General Meeting, Oct 10, 2023 Aug 29
New minor risk - Profitability Aug 13
AcelRx Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 10, 2023 Jul 29
New major risk - Shareholder dilution Jul 24
Acelrx Pharmaceuticals Inc. Regains Compliance with Nasdaq Minimum Bid Price Rule Jun 17
First quarter 2023 earnings released: EPS: US$0.006 (vs US$1.19 loss in 1Q 2022) May 12
Full year 2022 earnings released: EPS: US$5.73 (vs US$5.86 loss in FY 2021) Apr 02
Third quarter 2022 earnings released: US$0.92 loss per share (vs US$1.41 loss in 3Q 2021) Nov 16
AcelRx Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 14, 2022 Nov 04
AcelRx Pharmaceuticals Announces Presentation of a Large Cohort of Complex Plastic Surgery Procedures Performed with DSUVIA at Plastic Surgery The Meeting 2022 Nov 01 AcelRx Pharmaceuticals Announces Reverse Stock Split to Regain Compliance
Second quarter 2022 earnings released: EPS: US$0.48 (vs US$0.083 loss in 2Q 2021) Aug 13 AcelRx Pharmaceuticals, Inc. announced that it has received $0.3 million in funding from Lincoln Park Capital, LLC Aug 05
Nasdaq Grants Additional time to AcelRx Pharmaceuticals to Regain Compliance Jul 30
AcelRx Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 11, 2022 Jul 29 AcelRx Pharmaceuticals Receives Non-Compliance Notice from Nasdaq
AcelRx Pharmaceuticals, Inc. Provides Update on Reduced FDA REMS Requirements Related to DSUVIA May 20
First quarter 2022 earnings released: US$0.06 loss per share (vs US$0.079 loss in 1Q 2021) May 17
Acelrx Pharmaceuticals Announces Publication of Results from an Investigator-Initiated Trial on Sufentanil Sublingual Tablet (Sst) Compared to Standard Intravenous Opioids During Plastic Surgery Procedures Performed Under General Anesthesia May 12 AcelRx Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 16, 2022
AcelRx Pharmaceuticals, Inc. Announces Summary of Results from Podium Presentation on DSUVIA, at the Aesthetic Meeting 2022 Apr 26
AcelRx Pharmaceuticals, Inc. Announces Publication of A Study Evaluating the Use of A Sufentanil Sublingual Tablet 30 Mcg for Management of Pain of Radiofrequency Microneedling of the Face or Abdomen Apr 01
AcelRx Pharmaceuticals, Inc. Announces the Publication of Comparative Data Between Two Different Dialysis Circuit Anticoagulants in Pediatric Patients Undergoing Continuous Renal Replacement Therapy Mar 30
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Mar 12
AcelRx Pharmaceuticals, Inc. to Report Q4, 2021 Results on Mar 10, 2022 Mar 06
AcelRx Pharmaceuticals, Inc. Announces Resignation of Mark G. Edwards as Board of Director Mar 03
AcelRx Pharmaceuticals, Inc. Announces Publication of Clinical Data on the Use of Sufentanil Sublingual Tablet During Awake Plastic Surgery Procedures Feb 02
AcelRx Pharmaceuticals, Inc. (NasdaqGM:ACRX) completed the acquisition of Lowell Therapeutics, Inc. Jan 12
AcelRx Pharmaceuticals, Inc. Announces Publication of Clinical Data Showing Reduced Hospital Length of Stay and Reduced Opioid Utilization with Use of Sublingual Sufentanil in Total Joint Replacement Surgery Dec 16
Third quarter 2021 earnings released: US$0.07 loss per share (vs US$0.10 loss in 3Q 2020) Nov 16
Forecast to breakeven in 2022 Sep 23
Second quarter 2021 earnings released: US$0.083 loss per share (vs US$0.082 loss in 2Q 2020) Aug 18 AcelRx Pharmaceuticals, Inc.(NasdaqGM:ACRX) dropped from Russell 3000E Value Index Rosen Law Firm Reminds Purchasers of the Securities of Acelrx Pharmaceuticals, Inc. Between March 17, 2020 and February 12, 2021
Pomerantz Law Firm Announces the Filing of A Class Action Against AcelRX Pharmaceuticals, Inc. and Certain Officers Jun 09
AcelRx Pharmaceuticals, Inc. Announces Important Findings from A Podium Presentation on DSUVIA Jun 02
AcelRx Pharmaceuticals, Inc. Announces an Investigator-Initiated Study of DSUVIA in the Emergency Department for Patients with Sickle Cell Disease May 21
Forecast breakeven pushed back to 2023 May 19
First quarter 2021 earnings released: US$0.079 loss per share (vs US$0.20 loss in 1Q 2020) May 19
AcelRx Announces an Investigator-Initiated Study of DSUVIA® for Use in Same-Day Total Joint Replacement May 07
Full year 2020 earnings released: US$0.47 loss per share (vs US$0.67 loss in FY 2019) Mar 17
AcelRx Pharmaceuticals, Inc. to Report Q4, 2020 Results on Mar 15, 2021 Mar 09
AcelRx Announces an Investigator-Initiated Study of DSUVIA® in Patients Undergoing Plastic Surgery Procedures Feb 18
New 90-day high: €2.22 Feb 10
AcelRx Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $27.5 million. Jan 22
AcelRx Pharmaceuticals, Inc. Announces an Investigator-Initiated Study of DSUVIA® in Cardiac Surgery Enhanced Recovery Regimen Jan 20
New 90-day high: €1.65 Jan 17
New 90-day low: €0.94 Dec 31
New 90-day low: €1.07 Dec 16
AcelRx Pharmaceuticals, Inc. Announces Publication of Clinical Data on Decreased Postoperative Opioid Requirements and Enhanced Postanesthesia Recovery Following Perioperative Use of DSUVIA® Dec 11
AcelRx Pharmaceuticals Inc. Announces Partnership with the National Rural Health Association Dec 06
AcelRx Pharmaceuticals Announces Commentary in Practical Pain Management on Previously Published Clinical Data on Preoperative Administration of DSUVIA® Nov 19
Revenue misses expectations Nov 07
Third quarter 2020 earnings released: US$0.10 loss per share Nov 07
AcelRx Pharmaceuticals, Inc. to Report Q3, 2020 Results on Nov 05, 2020 Oct 30
New 90-day high: €1.59 Oct 12
AcelRx Pharmaceuticals, Inc. Secures United States Army Contract for DSUVIA Sep 23
New 90-day low - €0.90 Sep 15
First half earnings released Aug 11
AcelRx Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $10 million. Aug 11
AcelRx Pharmaceuticals, Inc. to Report Q2, 2020 Results on Aug 10, 2020 Aug 04 Shareholder Returns R5XA DE Pharmaceuticals DE Market 7D 21.5% 1.9% 2.3% 1Y -32.1% -12.6% 11.9%
See full shareholder returns
Return vs Market: R5XA underperformed the German Market which returned 11.9% over the past year.
Price Volatility Is R5XA's price volatile compared to industry and market? R5XA volatility R5XA Average Weekly Movement 14.5% Pharmaceuticals Industry Average Movement 5.5% Market Average Movement 4.8% 10% most volatile stocks in DE Market 10.8% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: R5XA's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: R5XA's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe.
Show more Talphera, Inc. Fundamentals Summary How do Talphera's earnings and revenue compare to its market cap? R5XA fundamental statistics Market cap €11.68m Earnings (TTM ) -€15.01m Revenue (TTM ) €269.73k
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) R5XA income statement (TTM ) Revenue US$281.00k Cost of Revenue US$7.16m Gross Profit -US$6.88m Other Expenses US$8.76m Earnings -US$15.64m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.92 Gross Margin -2,449.47% Net Profit Margin -5,565.48% Debt/Equity Ratio 67.7%
How did R5XA perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/23 03:47 End of Day Share Price 2025/01/23 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Talphera, Inc. is covered by 19 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution James Molloy Alliance Global Partners David Buck B. Riley Securities, Inc. Andrew D'Silva B. Riley Securities, Inc.
Show 16 more analysts 
